Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Rapid CommunicationAccelerated Communication

3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7)

Olivier Barbier, David Turgeon, Caroline Girard, Mitchell D. Green, Thomas R. Tephly, Dean W. Hum and Alain Bélanger
Drug Metabolism and Disposition May 2000, 28 (5) 497-502;
Olivier Barbier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Turgeon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Girard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitchell D. Green
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas R. Tephly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dean W. Hum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Bélanger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

3′-Azido-3′-deoxythymidine (AZT) is frequently prescribed to patients infected with the human immunodeficiency virus. After absorption, AZT is rapidly metabolized into 3′-azido-3′-deoxy-5′-glucuronylthymidine by UDP-glucuronosyltransferase (UGT) enzymes. Using labeled [14C]UDP-glucuronic acid and microsomal preparations from human kidney 293 cells stably expressing the different human UGT2B isoenzymes, it was demonstrated that AZT glucuronidation is catalyzed specifically by human UGT2B7. The identity of the metabolite formed was confirmed as AZT-G by liquid chromatography coupled with mass spectrometry. UGT2B7 is encoded by a polymorphic gene and kinetic analysis of AZT glucuronidation by the two allelic variants UGT2B7(H268) and UGT2B7(Y268), yielded apparent Km values of 91.0 and 80.1 μM, respectively. Normalization to protein levels yielded glucuronidation efficiency ratios (Vmax/Km) of 21.3 and 11.0 μl · min−1 · mg protein−1for UGT2B7(H268) and UGT2B7(Y268), respectively. It remains possible that other UGT enzymes are also involved in AZT conjugation; however, the glucuronidation of AZT by UGT2B7, which is a UGT2B protein expressed in the liver, is consistent with previous findings and supports the physiological relevance of this enzyme in AZT conjugation.

Footnotes

  • Send reprint requests to: Dr. Alain Bélanger or Dr. Dean W. Hum, Laboratory of Molecular Endocrinology, CHUL Research Center, 2705 Laurier Blvd., Quebec G1V 4G2, Canada. E-mail:Alain.Bélanger{at}crchul.ulaval.ca orDean.Hum{at}crchul.ulaval.ca

  • ↵1 These authors contributed equally to this work.

  • This work was supported by the Medical Research Council of Canada (A.B. and D.W.H.), the Fonds de la Recherche en Santé du Québec (A.B. and D.W.H.), Endorecherche and the National Institutes of Health (GM26221 to T.R.T.). Olivier Barbier and David Turgeon are holders of scholarships from La Fondation de l'Université Laval, and Caroline Girard is holder of a Summer Research Fellowship from the American Endocrine Society.

  • Abbreviations used are::
    HIV-RT
    HIV-reverse transcriptase
    AZT
    3′-azido-3′-deoxythimidine
    AZT-G
    3′-azido-3′-deoxy-5′-glucuronylthymidine
    AZT-TP
    AZT-5′-triphosphate
    UDPGA
    UDP-glucuronic acid
    HK293
    human kidney 293
    UGT
    UDP-glucuronosyltransferase
    LC-MS/MS
    liquid chromatography coupled with mass spectrometry
    • Received December 10, 1999.
    • Accepted February 16, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 28 (5)
Drug Metabolism and Disposition
Vol. 28, Issue 5
1 May 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7)
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rapid CommunicationAccelerated Communication

3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7)

Olivier Barbier, David Turgeon, Caroline Girard, Mitchell D. Green, Thomas R. Tephly, Dean W. Hum and Alain Bélanger
Drug Metabolism and Disposition May 1, 2000, 28 (5) 497-502;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Rapid CommunicationAccelerated Communication

3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7)

Olivier Barbier, David Turgeon, Caroline Girard, Mitchell D. Green, Thomas R. Tephly, Dean W. Hum and Alain Bélanger
Drug Metabolism and Disposition May 1, 2000, 28 (5) 497-502;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results and Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Use of CYP Transgenic Mouse Models
  • Nonlinear Metabolite Kinetics of Verapamil
  • Production of Recombinant hsa-mir-27b
Show more Accelerated Communication

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics